Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

被引：0
|
作者：
Hua, Y. [1 ]
Xu, W. [1 ]
Shi, H. [1 ]
Zheng, X. [1 ]
Li, X. [1 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
基金：
北京市自然科学基金;
关键词：
NSCLC; MET; savolitinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12D.07
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [31] Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC)
    Desai, Aakash
    Smith, Caleb J.
    Pritchett, Joshua C.
    Leventakos, Konstantinos
    West, Howard
    CANCER, 2024, 130 (16) : 2807 - 2811
  • [32] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Post-protocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC)
    Desai, Aakash
    Mansfield, Aaron Scott
    Kommalapati, Anuhya
    Leventakos, Konstantinos
    Adjei, Alex A.
    West, Howard Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 125 - 125
  • [34] NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC).
    Gregorc, Vanesa
    Zilembo, Nicoletta
    Grossi, Francesco
    De Pas, Tommaso M.
    Rossoni, Gilda
    Pietrantonio, Filippo
    Rijavec, Erika
    Giovannini, Monica
    Citterio, Giovanni
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Gronberg, B. H.
    Lund-Iversen, M.
    Strom, E. H.
    Brustugun, O. T.
    Scott, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
    Ryu, Rachel
    Ward, Kristina E.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [37] Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer
    Ban, Heejung
    Kim, Kyu-Sik
    Oh, In-Jae
    Yoon, Seong-Hoon
    Lee, Boram
    Yu, Jinyeong
    Kim, Sunmin
    Lee, Ho-Sung
    Shin, Hong-Joon
    Park, Cheol-Kyu
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    THORACIC CANCER, 2014, 5 (06) : 525 - 529
  • [38] Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
    Syrigos, K.
    Charpidou, A.
    Grapsa, D.
    Vassos, D.
    Tsimpoukis, S.
    Tsagouli, S.
    Gkiozos, I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S902 - S903
  • [39] Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
    Pluzanski, A.
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Migliorino, M. R.
    Niho, S.
    Nakagawa, K.
    Lee, K. H.
    Corral, J.
    Rosell, R.
    Linke, R.
    Tang, Y.
    Pastel, M.
    Wilner, K.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S617 - S618
  • [40] EFFICACY AND SAFETY OF CISPLATIN/PEMETREXED AS FIRST-LINE TREATMENT FOR JAPANESE PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Yamaguchi, Teppei
    Nakanishi, Toru
    Hayashi, Masamichi
    Isogai, Sumito
    Hoshino, Tami
    Mieno, Yuki
    Uozu, Sakurako
    Morishita, Mariko
    Okamura, Takuya
    Takeyama, Tomoko
    Minezawa, Tomoyuki
    Morikawa, Sayako
    Niwa, Yoshikazu
    Okazawa, Mitsushi
    Imaizumi, Kazuyoshi
    RESPIROLOGY, 2013, 18 : 83 - 83
12345